Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 18,156
- Companies
- 1,062
- Drugs tracked
- 3,385
Quick answer
NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
CABOZANTINIB, CABOZANTINIB, CABOZANTINIB, PLACEBO, CASDATIFAN
Arcus Biosciences
Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
1 trial -
Casdatifan
Arcus Biosciences
Metastatic Clear Cell Renal Cell Carcinoma
1 trial -
Domvanalimab
Arcus Biosciences
Advanced Upper Gastrointestinal Tract Adenocarcinoma
1 trial -
Durvalumab
Arcus Biosciences
Non-Small Cell Lung Cancer
1 trial -
FLUOROURACIL, CAPECITABINE, Zimberelimab, OXALIPLATIN, FLUOROURACIL, CALCIUM FOLINATE, DOMVANALIMAB, NIVOLUMAB, FLUOROURACIL, CAPECITABINE
Arcus Biosciences
Metastatic Esophageal or Gastric Cancer, Esophageal or Gastric Cancer
1 trial -
KEYTRUDA 25 mg/mL concentrate for solution for infusion, DOMVANALIMAB, AB122 (Zimberelimab)
Arcus Biosciences
Squamous Non-small cell Lung Cancer, Non-Small Cell Lung Cancer, Non squamous Non Small Cell Lung Cancer, Lung Cancer
1 trial -
Quemliclustat
Arcus Biosciences
Metastatic Pancreatic Ductal Adenocarcinoma
1 trial -
SALINE, GEMCITABINE, GEMCITABINE, Quemliclustat, GEMCITABINE, PACLITAXEL ALBUMIN-BOUND
Arcus Biosciences
Pancreatic cancer, Metastatic Pancreatic ductal adenocarcinoma (mPDAC), Pancreatic ductal adenocarcinoma (PDAC)
1 trial -
Volrustomig
Arcus Biosciences
Advanced Clear Cell Renal Cell Carcinoma
1 trial -
Zimberelimab
Arcus Biosciences
Non-small Cell Lung Cancer
2 trials -
AB680
Arcus Biosciences
Metastatic Colorectal Cancer
1 trial -
Atezolizumab
Arcus Biosciences
Prostate Adenocarcinoma
1 trial -
Casdatifan
Arcus Biosciences
Renal Cell Carcinoma
1 trial -
Domvanalimab
Arcus Biosciences
Advanced Non-Small Cell Lung Cancer
1 trial -
Domvanalimab
Arcus Biosciences
Gastrointestinal Tract Malignancies
1 trial -
Domvanalimab
Arcus Biosciences
Head and Neck Squamous Cell Carcinoma
1 trial -
Domvanalimab
Arcus Biosciences
Non Small Cell Lung Cancer
2 trials -
Etrumadenant
Arcus Biosciences
Prostatic Neoplasms, Castration-Resistant
1 trial -
Etrumadenant (AB928)
Arcus Biosciences
Rectal Cancer
1 trial -
Etrumadenant, Quemliclustat, FLUOROURACIL, BEVACIZUMAB, OXALIPLATIN, CALCIUM FOLINATE, Zimberelimab, Etrumadenant, REGORAFENIB
Arcus Biosciences
Metastatic colorectal cancer
1 trial -
Fluorouracil
Arcus Biosciences
Borderline Resectable Pancreatic Adenocarcinoma
1 trial -
Gemcitabine
Arcus Biosciences
Biliary Tract Carcinoma
1 trial -
OXALIPLATIN, CALCIUM FOLINATE, Quemliclustat, Zimberelimab, FLUOROURACIL, DOMVANALIMAB
Arcus Biosciences
Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies
1 trial -
Quemliclustat
Arcus Biosciences
Oligometastatic Prostate Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources